Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                               NOVAVAX, INC.
                 CONSOLIDATED STATEMENT OF OPERATIONS
          (in thousands, except per share and per share information)

                                                              Unaudited
                                                           Three-month ended
                                                         March 31,  March 31,
                                                           2009       2008
     Revenues:
         Total revenues                                     $21         458

     Operating costs and expenses:
       Research and development                           4,266       4,434
       General and administrative                         2,892       3,244

         Total operating costs and expenses               7,158       7,678

     Loss from continuing operations before interest     (7,137)     (7,220)
     Interest income, (loss), net                        (1,212)        117

     Loss from continuing operations                     (8,349)     (7,103)
     Loss from discontinued operations                        -        (652)

     Net loss                                            (8,349)     (7,755)

     Basic and diluted weighted average
       number of common shares used in
       computing basic net loss per share            68,692,455  61,280,155

     Basic and diluted net loss per share
       Loss per share from continuing operations         $(0.12)     $(0.12)
        Loss 
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. ... and patient recruitment services. The core expertise of PRC Clinical is focused on ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/29/2015)... ... 29, 2015 , ... Asymmetrex, LLC founder and ... the full range of capabilities of its unique cache of technologies for identifying, ... day-to-day renewal and repair of normal tissues and organs. This property makes them ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... Co. LP has partnered,with BlueStar Capital Management LP to ... partnership also gives Carl Marks a stake in BlueStar,Capital ... presence in the healthcare investment sector., The new ... and short public healthcare equities, in both managed accounts ...
... 28 Kiadis Pharma announced today,the presentation of the ... by Dr. Stephan Mielke* and Dr. John Barrett* of ... of the National,Institutes of Health (NIH) on Kiadis, lead ... in Anaheim, California., According to the NHLBI investigators ...
... News briefs concerning the,economic and business growth in ... SRI Launches First Major Project to Improve Port Security, ... million contract,to develop a Maritime Domain Awareness (MDA) System ... port security in,the United States. The contract was awarded ...
Cached Biology Technology:Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management 2Promising Data ATIR Studies Presented by NIH Investigators 2Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3Highlights of Economic and Business Growth in the Tampa Bay Region 4
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:7/2/2015)... June 25, 2015 Research ... the "Next Generation Biometrics Market by Application, Technology, ... report to their offering. The next generation ... 2020, at a CAGR of 17.9% between 2015 and ... application for the market. Safran SA ( ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... company as CEO to help further develop Genisphere,s therapeutics ... of partnering experience, having spent much of the last ... Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom ... on Technology and Biotech Corporate Finance. He graduated from ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... bushes and other greenery growing in the concrete-and-glass canyons of ... air pollutants by eight times more than previously believed, a ... in the ACS journal Environmental Science & Technology. ... dioxide (NO 2 ) and microscopic particulate matter (PM) ...
... of California, Riverside believe they can extend the range ... taking into account real-time traffic information, road type and ... who work at the Center for Environmental Research and ... of Engineering, have received a nearly $95,000 one-year grant ...
... Model S to the Nissan Leaf, run on rechargeable lithium-ion ... half of the vehicle,s total cost. One promising alternative ... more energy at a much lower cost. But lithium-sulfur ... of charging and discharging, the battery stops working. ...
Cached Biology News:Extending the range of electric vehicles 2Extending the range of electric vehicles 3Stanford-SLAC team uses X-ray imaging to observe running batteries in action 2Stanford-SLAC team uses X-ray imaging to observe running batteries in action 3Stanford-SLAC team uses X-ray imaging to observe running batteries in action 4
... an aqueous solution that contains a purified ... in a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... contains a combination of 0.02% methylisothiazolone, 0.02% ... and Haas Company) as a preservative. ...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... Microarray Gene Frame® has been specifically ... frames feature the same dual strength ... Frame® range for easy removal after ... and there are three sizes available. ...
... strength adhesive system which facilitates the easy removal ... either side of the frame are of differing ... has an easy release adhesive whereas the reverse, ... bond. This means that when the coverslip is ...
Biology Products: